Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?

被引:784
作者
Kobayashi, Hisataka [1 ]
Watanabe, Rira [1 ]
Choyke, Peter L. [1 ]
机构
[1] NCI, Ctr Canc Res, Mol Imaging Program, NIH, Bethesda, MD 20892 USA
来源
THERANOSTICS | 2014年 / 4卷 / 01期
关键词
Cancer; Nano-delivery; Tumor physiology; Enhanced permeability and retention effects; TRANSCAPILLARY PRESSURE-GRADIENT; MACROMOLECULAR DRUG-DELIVERY; INTERSTITIAL FLUID PRESSURE; TUMOR BLOOD-FLOW; SOLID TUMORS; LIPOSOMAL DOXORUBICIN; VASCULAR-PERMEABILITY; PHARMACO-ANGIOGRAPHY; CANCER; BREAST;
D O I
10.7150/thno.7193
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Nano-sized therapeutic agents have several advantages over low molecular weight agents such as a larger loading capacity, the ability to protect the payload until delivery, more specific targeting due to multivalency and the opportunity for controlled/sustained release. However, the delivery of nano-sized agents into cancer tissue is problematic because it mostly relies on the enhanced permeability and retention (EPR) effect that depends on the leaky nature of the tumor vasculature and the prolonged circulation of nano-sized agents, allowing slow but uneven accumulation in the tumor bed. Delivery of nano-sized agents is dependent on several factors that influence the EPR effect; 1. Regional blood flow to the tumor, 2. Permeability of the tumor vasculature, 3. Structural barriers imposed by perivascular tumor cells and extracellular matrix, 4. Intratumoral pressure. In this review, these factors will be described and methods to enhance nano-agent delivery will be reviewed.
引用
收藏
页码:81 / 89
页数:9
相关论文
共 83 条
  • [1] Akiyoshi K, 1996, EUR J PHARM BIOPHARM, V42, P286
  • [2] Drug delivery systems: Entering the mainstream
    Allen, TM
    Cullis, PR
    [J]. SCIENCE, 2004, 303 (5665) : 1818 - 1822
  • [3] Clinical aspects of drug delivery to tumors
    Au, JLS
    Jang, SH
    Wientjes, MG
    [J]. JOURNAL OF CONTROLLED RELEASE, 2002, 78 (1-3) : 81 - 95
  • [4] Interstitial fluid pressure in intracranial tumours in patients and in rodents
    Boucher, Y
    Salehi, H
    Witwer, B
    Harsh, GR
    Jain, RK
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (06) : 829 - 836
  • [5] Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery
    Canelas, Dorian A.
    Herlihy, Kevin P.
    DeSimone, Joseph M.
    [J]. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2009, 1 (04) : 391 - 404
  • [6] ABNORMAL RESPONSE OF TUMOR VASCULATURE TO VASOACTIVE DRUGS
    CHAN, RC
    BABBS, CF
    VETTER, RJ
    LAMAR, CH
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1984, 72 (01) : 145 - 150
  • [7] Chauhan VP, 2012, NAT NANOTECHNOL, V7, P383, DOI [10.1038/nnano.2012.45, 10.1038/NNANO.2012.45]
  • [8] Renal clearance of quantum dots
    Choi, Hak Soo
    Liu, Wenhao
    Misra, Preeti
    Tanaka, Eiichi
    Zimmer, John P.
    Ipe, Binil Itty
    Bawendi, Moungi G.
    Frangioni, John V.
    [J]. NATURE BIOTECHNOLOGY, 2007, 25 (10) : 1165 - 1170
  • [9] Clarke K, 2000, CLIN CANCER RES, V6, P3621
  • [10] Permeability to macromolecular contrast media quantified by dynamic MRI correlates with tumor tissue assays of vascular endothelial growth factor (VEGF)
    Cyran, Clemens C.
    Sennino, Barbara
    Fu, Yanjun
    Rogut, Victor
    Shames, David M.
    Chaopathomkul, Bundit
    Wendland, Michael F.
    McDonald, Donald M.
    Brasch, Robert C.
    Raatschen, Hans-Juergen
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2012, 81 (05) : 891 - 896